

QIBA CT Angiography Biomarker Committee (BC) Call

16 August 2022 at 11 AM CT

Call Summary

In Attendance

| | | |
|-------------------------------|---------------------------|--|
| Andrew Buckler, MS (Co-Chair) | Mathis Konrad, MSc | Edwin J.R. van Beek, MD, PhD... |
| Suhny Abbara, MD | Hugo Marques, MD, PhD | Todd Villines, MD-INMD |
| Jeffrey Carr, MD | Alastair J. Moss, MD, PhD | Renu Virmani, MD |
| James Kevin DeMarco, MD | Nancy Obuchowski, PhD | Michelle Williams, MBChB, PhD, MRCP... |
| Maros Ferencik, MD, PhD | Jim O'Doherty, PhD, MSc | Max Wintermark, MD, MS, MBA |
| Márton Kolossváry, PhD | Alexia Rossi, MD, PhD | |

RSNA Staff

Joe Koudelik
Julie Lisiecki

Moderator: Andrew Buckler, MS

Discussion topics:

- Overview of current Consensus [CTA Profile](#) (March 2020 version)
- The original Profile has been shortened for better utilization and impact
- Target audience and application need to be identified to optimize the Profile
- Plan to extend the current Profile (v2023) to include other pertinent areas for study with suggestions as follows:
 - Intra-plaque hemorrhage (IPH)
 - multi variable biomarkers, e.g., histology to find high risk plaque (as a prognostic phenotype)
 - blood vessel location
 - peripheral and intracranial vascular beds
 - Define the difference in the vascular beds (coronary/carotid)
 - Vascular / coronary artery fat, e.g., PVAT / PCAT
 - Fat attenuation index (FAI)
 - Proposal made to include / mention PVAT / PCAT to stimulate discussion in the field, but not associate with Profile claims at this time
 - high risk iris plaque
 - prognostic vs. predictive biomarkers
 - normalizing CT image acquisition
 - Photon counting (in the future)
- Possible Profile applications:
 - Clinical care to distinguish across different disease presentations
 - Drug development
 - Clinical trials
 - Post marketing activities to determine the effect on the plaques by various pharmacotherapy
 - Address higher spatial resolution for Photon Counting CT (PCCT)

Decisions / Action items (ongoing):

- Continue with the field testing of the 2020 Consensus Profile (volunteers needed)
- In order to achieve the next Profile stage, Clinically Feasible (formerly Technical Confirmation) (Stage 3), sites must complete feasibility testing of the Profile to demonstrate that it is implementable in a real-world setting
- Mr. Buckler recommended that at least 6 sites volunteer and proposed the following:
 - Two neurovascular sites
 - Two coronary sites
 - Two carotid artery sites

- Interested volunteers are asked to contact the co-chairs: [Mr. Buckler](#) and Drs. [Saba](#) and [Schoepf](#).

Links for more information:

- [Profile Stages](#)
- [CTA Profile \(March 2020 version\)](#)
- [Public Comment Resolution Page](#)
- http://qibawiki.rsna.org/index.php/CT_Angiography_Biomarker_Ctte
- Any feedback is welcome to the co-chairs: [Mr. Buckler](#) and Drs. [Saba](#) and [Schoepf](#).

Next call: Tuesday, August 30th at 11 am CT

Link to call recording: https://rsna-org.zoom.us/rec/share/4vZ4HfuRJVq15RHGTfjz79OuEf6oDuo_R32q_uoaluXnT0ZNBW6m3ugXGMuwsM1.TCVeCvoFqHJm3Um9?startTime=1660665285000

Passcode: **75?xF8z***